These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 17558895

  • 1. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G, Arena V, Maggiano N, Costarelli L, Crescenzi A, Zelano G, Amini M, Capelli A, Carbone A.
    Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
    [Abstract] [Full Text] [Related]

  • 2. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S.
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [Abstract] [Full Text] [Related]

  • 3. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C.
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [Abstract] [Full Text] [Related]

  • 4. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 5. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R, Lal P, Chen B.
    Am J Clin Pathol; 2005 Feb 01; 123(2):237-43. PubMed ID: 15842048
    [Abstract] [Full Text] [Related]

  • 6. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.
    Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A.
    Mod Pathol; 2001 Jul 01; 14(7):677-85. PubMed ID: 11455000
    [Abstract] [Full Text] [Related]

  • 7. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P, Henkel V, Speer R, Vogel U, Sotlar K, Aydeniz B, Reiser A, Neubauer H, Tabiti K, Wallwiener D, Clare SE, Kurek R.
    Anticancer Res; 2005 Jul 01; 25(3B):1895-900. PubMed ID: 16158923
    [Abstract] [Full Text] [Related]

  • 8. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ.
    Histopathology; 2006 Feb 01; 48(3):258-67. PubMed ID: 16430472
    [Abstract] [Full Text] [Related]

  • 9. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R, Apple SK, He J, Gornbein JA, Chang HR.
    Breast J; 2005 Feb 01; 11(6):433-9. PubMed ID: 16297088
    [Abstract] [Full Text] [Related]

  • 10. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M, Kodet R, Kalinová M, Hilská I.
    Pathol Res Pract; 2003 Feb 01; 199(7):453-61. PubMed ID: 14521261
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH.
    Hum Pathol; 2007 Sep 01; 38(9):1386-93. PubMed ID: 17555797
    [Abstract] [Full Text] [Related]

  • 12. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
    Potemski P, Płuciennik E, Bednarek AK, Kusińska R, Pasz-Walczak G, Jesionek-Kupnicka D, Watala C, Kordek R.
    Med Sci Monit; 2006 Dec 01; 12(12):MT57-61. PubMed ID: 17136015
    [Abstract] [Full Text] [Related]

  • 13. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT.
    Clin Cancer Res; 2008 Dec 01; 14(23):7861-70. PubMed ID: 19047115
    [Abstract] [Full Text] [Related]

  • 14. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma.
    Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM.
    Am J Clin Pathol; 2004 Jul 01; 122(1):110-9. PubMed ID: 15272539
    [Abstract] [Full Text] [Related]

  • 15. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
    Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW.
    Am J Clin Pathol; 2005 Aug 01; 124(2):273-81. PubMed ID: 16040300
    [Abstract] [Full Text] [Related]

  • 16. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S.
    Am J Clin Pathol; 2008 Apr 01; 129(4):563-70. PubMed ID: 18343783
    [Abstract] [Full Text] [Related]

  • 17. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
    Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, Weaver DL.
    Am J Clin Pathol; 2004 Aug 01; 122(2):246-55. PubMed ID: 15323142
    [Abstract] [Full Text] [Related]

  • 18. Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.
    Kulka J, Tôkés AM, Kaposi-Novák P, Udvarhelyi N, Keller A, Schaff Z.
    Pathol Oncol Res; 2006 Aug 01; 12(4):197-204. PubMed ID: 17189981
    [Abstract] [Full Text] [Related]

  • 19. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
    Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, Fiorentino M.
    Diagn Mol Pathol; 2008 Dec 01; 17(4):220-6. PubMed ID: 18382352
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ.
    Clin Cancer Res; 2005 Sep 15; 11(18):6598-607. PubMed ID: 16166438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.